title: [Tumor angiogenesis and tumor angiogenesis inhibitors].
abstract: It is important to survey the molecular targets which are involved in tumor angiogenesis for the development of antiangiogenic agents as one of the cancer therapy. This article is meant to review the recent molecular targets of tumor angiogenesis and the molecular mechanism of antiangiogenic agents in human clinical trials.
authors.affiliation: Dept. of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University.
authors.forename: M
authors.initials: M
authors.lastname: Ono
authors.forename: M
authors.initials: M
authors.lastname: Kuwano
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D043168:Angiostatins; D000818:Animals; D015703:Antigens, CD; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015820:Cadherins / Q000494:pharmacology; D066246:ErbB Receptors / Q000502:physiology; D000077156:Gefitinib; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D051379:Mice; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D000078183:Oxindoles; D010446:Peptide Fragments / Q000627:therapeutic use; D010958:Plasminogen / Q000627:therapeutic use; D011422:Propionates; D011758:Pyrroles / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D019010:Vascular Cell Adhesion Molecule-1 / Q000502:physiology; D000099152:Cadherin 5
chemical_list: D020533:Angiogenesis Inhibitors; D043168:Angiostatins; D015703:Antigens, CD; D000970:Antineoplastic Agents; D015820:Cadherins; D066246:ErbB Receptors; D000077156:Gefitinib; D007211:Indoles; D000078183:Oxindoles; D010446:Peptide Fragments; D010958:Plasminogen; D011422:Propionates; D011758:Pyrroles; D011799:Quinazolines; D019010:Vascular Cell Adhesion Molecule-1; D000099152:Cadherin 5; C116890:Semaxinib; C412603:orantinib